Table 2: Clinical and morphological characteristics of the study group





Parameters

No. of patients

Percentage of patients (%)

95% Confidence Interval


Age (years)

≤60

26

41.3

29.9 – 53.6

>60

37

58.7

46.4 – 70.1

Gender

Male

30

47.6

35.8 – 59.8

Female

33

52.4

40.2 – 64.3

Tumour localization

Pancreatic head

54

85.7

75.0 – 92.2

Other

9

14.3

7.8 – 25.0

Tumour size (cm)

≤2

4

9.1

3.7 – 21.2

>2

40

90.9

78.8 – 96.3

≥3

30

68.2

53.4 – 80.0

T stage

T1 and T2

3

4.8

1.8 – 13.3

T3 and T4

59

95.2

86.7 – 98.2

N stage

N0

20

32.8

22.3 – 45.3

N1

41

67.2

54.7 – 77.7

Tumour grade

Low

8

12.7

6.6 – 23.2

Moderate

39

61.9

49.5 – 72.9

High

16

25.4

16.3 – 37.4

Resection margins

Negative

28

48.3

35.9 – 60.9

Positive

30

51.7

39.1 – 64.1

Vascular and perivascular invasion

Absent

41

65.1

52.7 – 75.7

Present

22

34.9

24.3 – 47.3

Intraneural and perineural invasion

Absent

10

15.9

8.9 – 26.9

Present

53

84.1

73.1 – 91.1





Abbreviations. T1, tumour limited to the pancreas, 2cm or less in greatest dimension; T2, tumour limited to the pancreas, more than 2 cm in greatest dimension; T3, tumour extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery; T4, tumour involves the celiac axis or the superior mesenteric artery; N0, no regional lymph node metastasis; N1, regional lymph node metastasis [22].

Strumfa et al.Journal of Cancer Therapeutics and Research  2012 1:27DOI : 10.7243/2049-7962-1-27